louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02947984: Proton/Photon Rt - Benign Meningiomas(P92-13)
Official title: Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Benign Meningioma
Keywords: sphenoid region
parasellar area
photon radiation therapy
proton radiation therapy
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2016-10-28
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the best radiation dose for participants with meningioma that has grown back after previous surgery, or which the surgeon has been unable to remove completely. This research study is designed to determine whether a higher dose of radiation will decrease the likelihood that the tumor will grow back, compared to the probability of re-growth that occurs after standard radiation doses.

Detailed description: * After initial interview and physical examination, an immobilization device (head mask, neck support, back support, etc.) will be made for the participant. A treatment planning CT will be performed and a radiation treatment plan will be based on this CT scan.
* The radiation dose will usually be given once a day, five days per week. The radiation treatment will take between 7 and 8 1/2 weeks, including treatment planning.
* Treatment doses will vary, and the dose each participant will receive will be made on the basis of random assignment. Participants will either receive the usual dose of 55.8 CGE in 31 treatments or 1.8 CGE, or 63 CGE in 35 treatments of 1.8 CGE.

Eligibility criteria: Inclusion Criteria:

* Age 18 or over
* Histological documentation of benign meningioma
* Documentation by imaging studies (CT and/ or MRI) or residual or recurrent intracranial tumor
* Karnofsky performance status of ≥ 70
* Study specific informed consent

Exclusion Criteria:

* Malignant meningiomas
* Prior cranial irradiation, except treatment of localized skin cancer of the face or scalp
* Patients having a concurrent primary cancer (except skin)
* Patients having another cancer controlled \< 3 years
* Pregnant patients

Primary outcomes:
measure: Progression Free Survival
timeFrame: 5, 10, 15 years
Secondary outcomes:
measure: Acute Toxicities
timeFrame: 90 Days
measure: Late Toxicities
timeFrame: 5 Years
measure: Local Failure Rate
timeFrame: 15 Years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hosital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Helen A Shih, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00784979: Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation
Official title: Reduction of PRA (Panel Reactive Antibody) in Sensitized Patients Awaiting Live-Donor Renal Transplantation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: End Stage Renal Disease
Keywords: Renal
Transplant
PRA
Lead sponsor: Tampa General Hospital
Sponsor class: OTHER
Collaborators: name: CSL Behring
First posted: 2008-11-05
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to offer Panel Reactive Antibodies \[PRA\] reduction treatment to high responder renal transplant patients who otherwise may never be compatible with a potential organ donor. PRA reduction is offered in the following phases:

1. Immunological Testing
2. Transplant Nephrectomy
3. Pharmacologic Therapy
4. Plasmapheresis
5. Transplant

Detailed description: Patients with high level of preformed antibodies (panel reactive antibodies \[PRA\]) to donor antigens make identification of a suitable donor difficult. For most transplant centers, 20-35% of patients waiting for a kidney transplant comprise this challenging group. These patients have a wait time of over five years and have many incompatible cross-matches with potential organ donors.

Eligibility criteria: Inclusion Criteria:

* Renal transplant recipients with a potential living donor who is incompatible (T-\&/or B-cell locus) due to recipient high PRA or MHC antibodies
* PRA greater than or equal to 20% within last twelve months
* Recipient and donor accepted as potential candidates by the LifeLink Healthcare Renal Transplant Committee

Exclusion Criteria:

* Patients with known allergy to CytoGam(R), Cellcept, Rapamycin
* Patients who will receive IVIG or CytoGam(R) for any cause prior to protocol process
* ABO incompatibility
* Patients not capable of following through the treatment for various reasons as determined by treating physicians
* Any potential recipient who is pregnant or becomes pregnant
* Exclusion for Plasmapheresis: known allergy to ethylene oxide or natural rubber latex.
* Exclusion for Plasmapheresis: Intake of ACE-inhibitor or Angtiotensiin-receptor blockers in the last 24 hours prior to plasma exchange

Primary outcomes:
measure: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor
timeFrame: four weeks
Secondary outcomes:
measure: Monitor Graft Survival
timeFrame: 5 years
measure: Monitor Patient Survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Tampa
country: United States
facility: LifeLink HealthCare Institute
state: Florida
Study officials:
affiliation: Lifelink Healthcare Institute
name: John Leone, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01048879: Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)
Official title: Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving CVVHD and/or ECMO
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Critically Ill Renal Failure Requiring CVVHD and Oseltamivir
Critically Ill Requiring ECMO and Oseltamivir
Keywords: oseltamivir
influenza
continuous renal replacement therapy
extracorporeal membrane oxygenation
pharmacokinetics
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Roche Pharma AG
First posted: 2010-01-14
Enrollment: 15
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Critically ill patients with flu may receive a drug called oseltamivir. They may also receive medical therapies to support their lung function (extracorporeal membrane oxygenation; ECMO) and kidney function (continuous venovenous hemodialysis; CVVHD). CVVHD and ECMO may remove some oseltamivir from the bloodstream. The purpose of this study is to determine how much oseltamivir gets removed by CVVHD or ECMO in critically ill patients.


Eligibility criteria: Inclusion Criteria:

* receiving Continuous Venovenous Hemodialysis (CVVHD) or Extracorporeal Membrane Oxygenation (ECMO)
* require oseltamivir treatment
* informed consent granted

Exclusion Criteria:

* pregnant
* unable to complete 12 hours of CVVHD or ECMO
* \<6 kg body weight
* allergy to oseltamivir

Primary outcomes:
measure: Continuous Venovenous Hemodialysis (CVVHD)Oseltamivir Carboxylate Transmembrane Clearance
timeFrame: 12 hours
measure: Oseltamivir Carboxylate Removal by ECMO
timeFrame: 12 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Hospital
state: Michigan
Study officials:
affiliation: University of Michigan
name: Bruce A Mueller, Pharm.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Eyler RF, Heung M, Pleva M, Sowinski KM, Park PK, Napolitano LM, Mueller BA. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy. 2012 Dec;32(12):1061-9. doi: 10.1002/phar.1151.
Clinical trial NCT02695979: Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation
Official title: Changes of Macrophage Migration Inhibitory Factor and Thyroid Hormones During Liver Transplantation. Association With Graft Dysfunction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Evidence of Liver Transplantation
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2016-03-02
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing orthotopic liver transplantation

Brief summary: Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.

Detailed description: Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function.

Eligibility criteria: Inclusion Criteria:

* End stage liver disease, chronic liver failure, orthotopic liver transplantation

Exclusion Criteria:

* Combined transplantations (liver plus kidney or lung), age under 18 y, acute liver failure

Primary outcomes:
measure: Macrophage Migration Inhibitory Factor in human serum, liver graft effluent and urine
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
measure: Acute kidney injury, outcome
timeFrame: 48 months
Locations:
city: Vienna
country: Austria
facility: Medical University Vienna
Study officials:
affiliation: Medical University Vienna, Department of Anesthesia, General Intensive Care and Pain Management
name: Peter Faybik, Prof
role: STUDY_CHAIR
References:
Clinical trial NCT03576079: Effect of Laser Therapy Versus Anterior Re-positioning Splint in the Treatment of Disc Displacement With Reduction
Official title: Effect of Laser Irradiation Versus Anterior Repositioning Splint in Treatment of Disc Displacement With Reduction A Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Temporomandibular Joint Disorders
Keywords: laser therapy
anterior re-positioning splint
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-07-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: comparing the effects of Laser therapy with anterior re-positioning splint and a placebo group on clinical signs and symptoms of temporo-mandibular dis-function and assessing articular disc morphology and configuration with magnetic resonance imaging.

Detailed description: to compare the clinical effects of Laser therapy as assessed with research diagnostic criteria of temporo-mandibular disorders to a group that received anterior re-positioning splint therapy and a control group that received placebo Laser. Diagnosis for disc displacement with reduction was performed with magnetic resonance imaging before treatment. assessment of the clinical and MRI findings was again performed after a 3 months observation period.

Eligibility criteria: Inclusion Criteria:

1. Patients having TMD in the form of disc displacement with reduction as verified from signs and symptoms during clinical examination and confirmed from the MRI.
2. Good general health: The patient must be medically free from any systemic disease or health problems.
3. Adult patients 18 years old and above.
4. No previous orthodontic treatment.
5. No previous TMJ treatment or surgery.

Exclusion Criteria:

1. Patients with multiple missing posterior teeth.
2. Muscle pain due to systemic disease.
3. Dental related pain.
4. Congenital abnormality, neoplasia or acute trauma.
5. Previous TMJ treatment or surgery.
6. Any medical condition that prohibits MRI acquisition.

Primary outcomes:
measure: Level of temporomandibular joint pain: assessed by using subjective visual analogue scale
timeFrame: 3 months
Secondary outcomes:
measure: click: joint sound
timeFrame: 3 months
measure: limitation of mandibular movements
timeFrame: 3 months
measure: disc recapture
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
affiliation: Professor of Orthodontics, Faculty of Dentistry, Cairo Universitye
name: Mona S Fayed, PHD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04146779: Yoga Intervention in Head and Neck Cancer Patients Undergoing Concurrent Chemo-Radiation
Official title: Feasibility Study of a Yoga Intervention in Head and Neck Cancer Patients Undergoing Concurrent Chemo-Radiation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Head and Neck Cancer
Lead sponsor: Vanderbilt-Ingram Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2019-10-31
Enrollment: 19
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a randomized prospective pilot study assessing the safety and feasibility of two yoga interventions in head and neck cancer patients undergoing primary or adjuvant radiation with or without concurrent chemotherapy

Detailed description: Primary Objective:

- To assess the safety and feasibility of Hatha yoga in head and neck cancer patients undergoing treatment with primary or adjuvant radiation with or without chemotherapy.

Eligibility criteria: Inclusion Criteria:

* Locally advanced, non-metastatic, histologically confirmed malignancy involving the head and neck region

  o Larynx, pharynx, oral cavity, salivary gland, paranasal sinuses and unknown primary
* Age greater or equal to 21 years of age
* Planned for either definitive or adjuvant radiation therapy with or without chemotherapy

  o Patients may have received induction chemotherapy or primary surgical resection prior to proceeding to radiation therapy
* Ability to understand English
* Daily access to the internet
* Willing and able to sign informed consent
* Willing and able to participate in yoga sessions as outlined in the study protocol

Exclusion criteria:

* Prior head and neck cancer radiation
* Patients who in the opinion of the treating physician are physically, medically or psychologically impaired to the point that participation is not deemed appropriate or feasible

Primary outcomes:
measure: Safety of Hatha yoga
timeFrame: Approximately 8 weeks
measure: Feasibility of Hatha yoga
timeFrame: Approximately 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt-Ingram Cancer Center
state: Tennessee
Study officials:
affiliation: Vanderbilt-Ingram Cancer Center
name: Barbara Murphy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06759779: Inspiratory and Expiratory Muscle Training in Adolescent Volleyball Players
Official title: Effects of Inspiratory and Expiratory Muscle Strength Training on Respiratory Functions and Performance in Adolescent Volleyball Players
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Adolescent Development
Keywords: pulmonary functions
muscle training
adolescent health
volleyball players
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2025-01-06
Enrollment: 26
Sex: FEMALE
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will investigate the effects of inspiratory and expiratory muscle training on respiratory muscle strength, pulmonary function, and performance status in adolescent athletes

Detailed description: In the literature, it has been shown in a limited number of studies that respiratory muscle training in sports such as football, cycling, swimming, and rugby reduces athletes' perceived exertion levels. However, the effects of inspiratory and expiratory muscle training on respiratory muscle strength, pulmonary function, and performance status in adolescent athletes are still unclear. Therefore, this study has been planned.

Eligibility criteria: Inclusion Criteria:

* Athletes aged 12-18 who train at a submaximal level at least 3 days a week

Exclusion Criteria:

* Adolescents with any history of chronic lung disease
* unable to comply with the test and training
* unwilling to participate in the study

Primary outcomes:
measure: Respiratory muscle strength
timeFrame: First day
Secondary outcomes:
measure: Constant load-inspiratory muscle endurance test
timeFrame: First day
measure: FEV1
timeFrame: First day
measure: FVC
timeFrame: First day
measure: FEV1/FVC
timeFrame: First day
measure: PEF
timeFrame: First day
measure: FEF2575
timeFrame: First day
measure: Athletic performance
timeFrame: second day
measure: Fat free mass Body compositions
timeFrame: second day
measure: Fat mass Body compositions
timeFrame: second day
measure: Fat percentage Body compositions
timeFrame: second day
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University
state: Emek
Study officials:
References:
Clinical trial NCT00968279: Coronary CT Angiography Using 320-Row Volume CT in Patients With Atrial Fibrillation
Official title: Coronary CT Angiography Using 320-Row Volume CT in Patients With Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Keywords: Patients with atrial fibrillation
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2009-08-28
Enrollment: 54
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with atrial fibrillation scheduled to undergo coronary angiography due to suspected coronary artery disease.

Brief summary: The primary objective of this study is to analyze the diagnostic accuracy of coronary CT angiography using 320 simultaneous detector results in patients with atrial fibrillation.


Eligibility criteria: Inclusion Criteria:

* Suspected coronary artery disease based on clinical findings or findings on other noninvasive imaging tests and planned coronary angiography within the next 14 days.
* Able to understand and willing to sign the Informed CF.

Exclusion Criteria:

* Creatinine of above 2.0 mg/dl
* Age below 50 years
* Women of child bearing potential (no hysterectomy, no menopause, or menopause since less than 12 months) must demonstrate a negative pregnancy test performed within 24 hours before CT.
* Inability to hold the breath for 10 seconds

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité
Study officials:
affiliation: Charité
name: Marc Dewey, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Zimmermann E, Dewey M. Whole-heart 320-row computed tomography: reduction of radiation dose via prior coronary calcium scanning. Rofo. 2011 Jan;183(1):54-9. doi: 10.1055/s-0029-1245629. Epub 2010 Aug 19.
citation: Dewey M, Zimmermann E, Deissenrieder F, Laule M, Dubel HP, Schlattmann P, Knebel F, Rutsch W, Hamm B. Noninvasive coronary angiography by 320-row computed tomography with lower radiation exposure and maintained diagnostic accuracy: comparison of results with cardiac catheterization in a head-to-head pilot investigation. Circulation. 2009 Sep 8;120(10):867-75. doi: 10.1161/CIRCULATIONAHA.109.859280. Epub 2009 Aug 24.
citation: Dewey M, Oncel D, Oncel G, Tastan A. Coronary CT angiography in patients with atrial fibrillation. Radiology. 2008 Aug;248(2):701; author reply 701-2. doi: 10.1148/radiol.2482080062. No abstract available.
Clinical trial NCT00925379: Renal HYPODYSPLASIA : Genetic and Familial Assessment
Official title: Renal HYPODYSPLASIA;Study of Familial Cases and Search for Predisposing Genes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Renal HYPODYSPLASIA, Nonsyndromic, 1
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2009-06-22
Enrollment: 342
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with a bilateral renal hypodysplasia

Brief summary: Evaluation of the frequency of familial cases of renal HYPODYSPLASIA

Detailed description: DNA collection from the propositus and its family. A questionnaire will be filled by the parents to seek other affected individual in the family.With another affected member, DNA collection will be collected from the whole family.

A renal ultrasound will be prescribed for the parents, brothers and sisters.

Eligibility criteria: Inclusion criteria :

- Children aged more than 3 months and less than 18 years old with a renal bilateral HYPODYSPLASIA set by renal ultrasound examination :

* renal size \< -2DS
* with/or hyperechogenicity or lack of cortical-medullary differentiation
* with/or renal cysts

Exclusion criteria :

* Bladder uropathy or sus-bladder uropathy
* Recessive or dominant renal polycystic disease
* Bardet-Biedl syndrome and other malformative syndromes except renal coloboma syndrome, Renal cysts and diabetes syndrome RCAD
* Lack of written informed consent

Primary outcomes:
measure: Evaluation of the heritability of renal HYPODYSPLASIA (on the renal ultra sound) and DNA collection to make possible identification of predisposing genes
timeFrame: the same day
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Necker Hospital
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Remi Salomon, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital, Limoges
name: Vincent Guigonis, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: